Explore
Validate
LearnPP-A8620A-00
antibody from R&D Systems
Targeting: EHMT2
BAT8, C6orf30, Em:AF134726.3, G9A, KMT1C, NG36/G9a
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PP-A8620A-00 - Provider product page
- Provider
- R&D Systems
- Product name
- Human/Mouse G9a/EHMT2 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. This antibody specifically recognizes mouse G9a and cross-reacts with human G9a. Not yet tested in other species.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- A8620A
- Vial size
- 100 ug
- Storage
- This antibody is stable for greater than six months when held at -20° C in a manual defrost freezer or at -70°C. Upon thawing, the antibody can be stored at 2° - 8° C for at least 1 month without detectable loss of activity. Avoid repeated freeze-thaw cycles.
Submitted references Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions.
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.
The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity.
Li L, Liu W, Wang H, Yang Q, Zhang L, Jin F, Jin Y
Cell death & disease 2018 May 1;9(5):480
Cell death & disease 2018 May 1;9(5):480
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
Chen RJ, Shun CT, Yen ML, Chou CH, Lin MC
Oncotarget 2017 Sep 22;8(37):62081-62098
Oncotarget 2017 Sep 22;8(37):62081-62098
Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Liu CW, Hua KT, Li KC, Kao HF, Hong RL, Ko JY, Hsiao M, Kuo ML, Tan CT
Molecular cancer therapeutics 2017 Jul;16(7):1421-1434
Molecular cancer therapeutics 2017 Jul;16(7):1421-1434
Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.
Li KC, Hua KT, Lin YS, Su CY, Ko JY, Hsiao M, Kuo ML, Tan CT
Molecular cancer 2014 Jul 15;13:172
Molecular cancer 2014 Jul 15;13:172
The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, Zhang R, Krosl J, Yung E, Kirschner J, Rosten P, Underhill TM, Jin J, Hébert J, Sauvageau G, Humphries RK, Rossi FM
Genes & development 2014 Feb 15;28(4):317-27
Genes & development 2014 Feb 15;28(4):317-27
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH, Chien MH, Yang CJ, Huang MS, Hsiao M, Kuo ML
Cancer research 2010 Oct 15;70(20):7830-40
Cancer research 2010 Oct 15;70(20):7830-40
DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity.
Dong KB, Maksakova IA, Mohn F, Leung D, Appanah R, Lee S, Yang HW, Lam LL, Mager DL, Schübeler D, Tachibana M, Shinkai Y, Lorincz MC
The EMBO journal 2008 Oct 22;27(20):2691-701
The EMBO journal 2008 Oct 22;27(20):2691-701
No comments: Submit comment
No validations: Submit validation data